During the last session, Relay Therapeutics Inc. (NASDAQ:RLAY)’s traded shares were 0.77 million. At the end of the trading day, the stock’s price was $26.80, reflecting an intraday loss of -3.74% or -$1.04. The 52-week high for the RLAY share is $64.37, that puts it down -140.19 from that peak though still a striking 4.03% gain since the share price plummeted to a 52-week low of $25.72. The company’s market capitalization is $2.97B, and the average intraday trading volume over the past 10 days was 0.42 million shares, and the average trade volume was 788.53K shares over the past three months.
Relay Therapeutics Inc. (RLAY) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. RLAY has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.58.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Relay Therapeutics Inc. (RLAY) registered a -3.74% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.74% in intraday trading to $26.80 this Friday, 01/07/22, hitting a weekly high. The stock’s 5-day price performance is -12.73%, and it has moved by -13.13% in 30 days. Based on these gigs, the overall price performance for the year is -34.10%. The short interest in Relay Therapeutics Inc. (NASDAQ:RLAY) is 14.25 million shares and it means that shorts have 27.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $50.50, which implies an increase of 46.93% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $45.00 and $54.00 respectively. As a result, RLAY is trading at a discount of -101.49% off the target high and -67.91% off the low.
Relay Therapeutics Inc. (RLAY) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -182.90% this quarter and then drop -27.70% in the quarter after that. In the rating firms’ projections, revenue will decrease -92.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $3.84 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $170k by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $82.65 million and $952k respectively. In this case, analysts expect current quarter sales to shrink by -95.40% and then drop by -82.10% in the coming quarter.
While earnings are projected to return -195.40% in 2022.
Relay Therapeutics Inc. is due to release its next quarterly earnings between March 23 and March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Relay Therapeutics Inc. (NASDAQ:RLAY)’s Major holders
Relay Therapeutics Inc. insiders own 3.51% of total outstanding shares while institutional holders control 84.75%, with the float percentage being 87.84%. SB Investment Advisers (UK) LTD is the largest shareholder of the company, while 213 institutions own stock in it. As of Sep 29, 2021, the company held over 27.9 million shares (or 25.83% of all shares), a total value of $879.84 million in shares.
The next largest institutional holding, with 13.69 million shares, is of FMR, LLC’s that is approximately 12.67% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $431.54 million.
Also, the Mutual Funds coming in first place with the largest holdings of Relay Therapeutics Inc. (RLAY) shares are Fidelity OTC Portfolio and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Oct 30, 2021 indicates that Fidelity OTC Portfolio owns about 2.51 million shares. This amounts to just over 2.33 percent of the company’s overall shares, with a $83.59 million market value. The same data shows that the other fund manager holds slightly less at 1.63 million, or about 1.51% of the stock, which is worth about $51.54 million.